VERAXA Biotech AG (NASDAQ: VRXA), a developer of next-generation antibody-based cancer therapies, has provided an update on its strategy to implement U.S. Food and Drug Administration (FDA)-aligned New Approach Methodologies (NAMs) across its preclinical research and development programs. The company said the approach could accelerate clinical advancement, reduce development costs and timelines, and significantly reduce animal testing.
VERAXA has built a panel of NAMs to characterize and de-risk its pipeline of BiTAC-based T cell engagers, antibody-drug conjugates (ADCs), and bispecific antibody-drug conjugates (bsADCs). According to the company, its lead BiTAC-TCE and bsADC candidates were evaluated using an ex vivo panel of 10 low-passage patient-derived xenograft models of non-small cell lung cancer. This panel required about 10 mice in total, compared with an estimated 200 or more for comparable in vivo efficacy studies. Across the panel, the combined BiTAC consistently induced potent T cell-mediated killing, supporting the company’s dual-targeting approach and demonstrating how its NAM strategy can reduce animal use and preclinical cycle time without compromising clinical relevance.
The implications of this announcement extend beyond VERAXA’s own pipeline. By aligning with FDA’s efforts to modernize toxicology testing, VERAXA is positioning itself at the forefront of a broader shift in drug development. If successful, its NAM strategy could set a precedent for other biotechnology companies, potentially leading to industry-wide reductions in animal testing and faster, more cost-effective paths to clinical trials. For patients, this could mean quicker access to novel cancer therapies. For investors, it signals a commitment to efficiency and regulatory alignment that may enhance the company’s competitive edge.
VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology. BiTAC(R) is a registered trademark of VERAXA Biotech GmbH. The company’s focus on next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs, and other innovative formats, is powered by a suite of transformative technologies and guided by rigorous quality-by-design principles.
To view the full press release, visit https://ibn.fm/9YRJw. The latest news and updates relating to VRXA are available in the company’s newsroom at http://ibn.fm/VRXA.
BioMedWire, a specialized communications platform focused on the biotechnology, biomedical sciences, and life sciences sectors, is one of 75+ brands within the Dynamic Brand Portfolio @ IBN. The platform delivers access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, and enhanced press release enhancement to ensure maximum impact.
For more information, please visit BioMedWire. Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer.
